Evidence map›Paper›PMID 40552291›Full record

ArticleFrontiers in immunology2025

Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method.

Kanghyun Choi, Joo-Young Lee, Uk-Il Kim, So-Hyun Park, So-Hee Hong, Yoo-Jin Bang, Yun-Ho Hwang, Jong-Eun Lee, Suhyun Park, Soochong Kim and 27 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A novel and safe SmartCapFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Kanghyun Choi *R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Joo-Young Lee *R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Uk-Il Kim *R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
So-Hyun Park *College of Veterinary Medicine, Chungbuk National University, Cheongju-si, Republic of Korea.
So-Hee Hong *Department of Microbiology, College of Medicine, Ewha Womens University, Seoul, Republic of Korea.
Yoo-Jin Bang *Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Yun-Ho Hwang *Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Jong-Eun Lee *Department of Life Science, Sogang University, Seoul, Republic of Korea.
Suhyun ParkR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Soochong KimCollege of Veterinary Medicine, Chungbuk National University, Cheongju-si, Republic of Korea.
Sunhee LeeR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Ye-Jin YunR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Tae-Gi UhmR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Inyoung LeeR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Minju KwonR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
EunJi KwonR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Suyeon SongR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Yongkyoung KweonR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Heejene KimR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Eun-Young OhCollege of Veterinary Medicine, Chungbuk National University, Cheongju-si, Republic of Korea.
Jae-Yong KimDepartment of Medical and Biological Sciences, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Tae-Young LeeDivision of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Seo-Yeon KimDivision of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Se-Eun KimDivision of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
You-Jin KimDivision of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Seonock LeeDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Ruijing SunDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Eun-Joo LeeDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Gamin KimDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Hanah LimDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Byungkyun KimR&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Jungho KimDepartment of Life Science, Sogang University, Seoul, Republic of Korea.
Dokeun KimDivision of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Jae-Hwan NamDepartment of Medical and Biological Sciences, The Catholic University of Korea, Bucheon-si, Republic of Korea.
Sang-Myeong LeeCollege of Veterinary Medicine, Chungbuk National University, Cheongju-si, Republic of Korea.
Kyungjin Kim *R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.
Joo-Sung Yang *R&D Center, ST Pharm Co., Ltd., Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Messenger RNA (mRNA) vaccines represent a critical avenue for coronavirus disease 2019 (COVID-19) prevention. We developed a COVID-19 mRNA vaccine encoding a codon-optimized full-length ancestral spike (S) protein with a signal peptide, which employs our novel patented co-transcriptional 5'-capping reagent, SmartCap

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansMiceMice, TransgenicmRNA VaccinesRNA, MessengerSpike Glycoprotein, CoronavirusVaccines, SyntheticACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic5′-cap analoguescapping library screeningCOVID-19mRNA vaccineSARS-CoV-2SmartCap ®STP2104

Identifiers

PMID40552291
PMCPMC12183165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.